Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NeuroSearch publishes promising meta-analysis of Huntexil studies

This article was originally published in Scrip

Executive Summary

NeuroSearch, the Danish CNS-focused biotech, has published the results of a meta-analysis of pooled datasets from two previous trials – the Phase IIb HART and Phase III MermaiHD studies -- corroborating earlier conclusions that Huntexil (pridopidine), 45 mg twice daily, has potential to treat Huntington's disease. NeuroSearch intends to include the results of the meta-analysis in the clinical data package on Huntexil, which the company plans to present to and discuss with US and European regulators during the first half of 2011.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts